Emily C. Daugherty, MD is an assistant professor of Radiation Oncology in the College of Medicine at the University of Cincinnati. She is the Lead Sub-Investigator on the Varian-sponsored FLASH FAST-01 study: Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases (VAR-2019-02). She joined the University of Cincinnati Medical Center in 2018. Dr. Daugherty specializes in the use of conventional and proton radiation therapy for the treatment of thoracic malignancies, oligometastases, and breast cancer. Dr. Daugherty is a physician leader on the UC Health/Cincinnati Children’s Hospital Medical Center FLASH Radiotherapy Research Team and is a member of the FlashForward Consortium. She has many physician leadership roles at the University of Cincinnati Cancer Center (UCCC), including serving as the Lung Cancer Leader for the UCCC Clinical Trial Council as well as an active member of the UCCC Lung Cancer Center of Excellence and Data Safety Monitoring Board. She is the Lung and Breast Cancer Expert for the UCCC Clinical and Translational Research Executive Committee. Dr. Daugherty serves as the institutional principal investigator for several industry-sponsored and cooperative group trials in lung cancer and oligometastatic disease. Dr. Daugherty was elected as an American Society of Radiation Oncology (ASTRO) Representative to the American Association of Physicists in Medicine (AAPM) Big Data Subcommittee. She has a particular interest and expertise in the development and implementation of new treatment strategies for lung malignancies, the use of radiotherapy in oligometastatic cancer, as well as quality improvement and standardization in radiation oncology.

Professor Eric Deutsch is a radiation oncologist and specialist in therapeutic innovations applied to tumor irradiation. He is the head of the Gustave Roussy Radiotherapy Department and leads the Institute's "Teaching and University Relations" division. With a doctorate in Radiobiology, Eric Deutsch is a professor of oncology-radiotherapy at the University of Paris-Saclay, where he teaches oncology and radiobiology. Head of the Inserm 1030 joint research unit "Molecular Radiotherapy and Therapeutic Innovation", Prof. Deutsch's research work is devoted to the study of the combination of new anticancer drugs with radiotherapy. His interest is focused on understanding the biological effects of radiotherapy, the interaction of the tumor with its microenvironment and the mechanisms of cell death. More recently, he has developed a research activity dedicated to radiomics and artificial intelligence in order to personalize treatments by radiotherapy combined with immunotherapy. Eric Deutsch is strongly involved in early clinical trials and in gastrointestinal cancers.

Fabio Di Martino is a Medical Physicist at the Unit of Health Physics of the University-Hospital of Pisa (Italy). His interests of research are mainly in the field of Dosimetry, Radiobiology in Radiotherapy and quantification problems in Nuclear Medicine. He is the author of more than 40 peer review publications in international journals. He has developed and patented a new theory that allows the realization of a new gas chamber for the absolute dosimetry of ultra high dose per pulse electron beams.

Prof. Valentin Djonov MD University of Berne, Switzerland The main scientific interest of Valentin Djonov’s group is the radio-biological effects induced by Microbeam Radiation Therapy (MRT). MRT is a preclinical radiotherapy technique using spatially fractionated X-rays to produce alternating regions of high and low dose deposition in the target tissue. This results in unique radiation/tissue interactions that expands the therapeutic index of radiation therapy by increasing tumor control, including that of radioresistant malignancies, while simultaneously exhibiting remarkable normal tissue sparing even when delivering peak doses of hundreds of Grays. This "MRT effect" appears to be governed by a new radiobiological paradigm characterized by several novel mechanisms that contribute to treatment success: (i) MRT acts as a very potent angiodisruptive and anti-angiogenic agent resulting in reduced blood supply to irradiated tumors (ii) these disrupted tumor vessels serve as a gateway for circulating immune cells to invade MRT-irradiated tumor tissue, and enhance anti-tumor immune responses (iii) this MRT-induced immune effect is characterized by a specific gene signature that implicates myeloid cell recruitment and interferon responses as key mediators of this anti-tumor response. These unique features support the clinical translation of MRT as a novel therapeutic approach for the treatment of inoperable, radioresistant lesions.

Dr. Dokic received degree in Molecular Biology and Physiology from the University of Belgrade, Serbia, a Ph.D. degree in Biosciences from the University of Heidelberg and German Cancer Research Center (DKFZ) in Germany in 2012. During her postdoctoral training at the DKFZ, she focused on tumor biology resistance mechanisms of glioblastoma. In 2013 she joined Radiation Oncology Department at Heidelberg University Hospital (UKHD), where she investigated radiation effects on brain tumors. In 2014 she continued her postdoctoral training in Clinical Cooperation Unit Molecular and Translational Radiation Oncology headed by Prof. Abdollahi, at Center for Tumor Diseases (NCT), Heidelberg Ion-Beam Therapy Center (HIT), DKFZ, and UKHD. Since 2019 she leads the Particle Radiobiology Group at NCT/HIT/UKHD, focusing on the biological effects and mechanisms of particle irradiation and translational applications of different irradiation modalities, including FLASH radiotherapy with particle beams. She is currently a co-PI or key scientist in multiple national and international collaborative research grants.

European Organization for Nuclear Research (CERN), Switzerland and University of Oxford, UK Manjit Dosanjh is the Project Leader for STELLA (Smart Technologies to Extend Lives with Linear Accelerators), honorary CERN Staff, the particle physics laboratory in Geneva, Switzerland and Visiting Professor at the University of Oxford. She holds a PhD in Biochemical Engineering from the UK and her professional efforts in the fields of biology and the medical applications of physics span more than 30 years, during which she has held positions in various academic and research institutions in Europe and the U.S., including the Massachusetts Institute of Technology, the Lawrence Berkeley National Laboratory at the University of California, the European Commission Joint Research Centre in Italy. Dosanjh joined CERN in 1999 where she has worked to apply technologies originally developed for particle physics to the domain of life sciences, aiming to translate and transfer knowledge about physics to society at large. She is a “bridge builder” among disciplines, people, cultures, and countries, amply demonstrated by ENLIGHT (European Network Light Ion Hadron Therapy) network, SEEIIST-Balkan collaboration and now the STELLA (Smart Technologies to Extend Lives with Linear Accelerators) collaboration in Africa and beyond. This and other current related activities including FLASH related research are all addressing improving access to cancer treatment globally.She is also actively involved in helping non-profit health, science education and gender related organisations in Geneva.

Prof. Xiaobo Du MD, PhD, doctoral supervisor, is Vice president, chief physician and professor of Mianyang Hospital affiliated to University of Electronic Science and Technology of Sichuan Province, China. He obtained a bachelor's degree in medicine from Chongqing Medical University and joined the oncology Department of Mianyang Central Hospital in 1995. From 2002 to 2006, he received a doctor's degree in West China Hospital of Sichuan University under the guidance of Academician Yuquan Wei. He served as the director of oncology department in 2009 and was appointed as the chief physician of oncology in 2010. In 2014. He served as the deputy director of Mianyang Central Hospital in 2019. He led the team to explore the technical innovation and clinical application of precise radiotherapy for tumors. Especially carried out five multi-center prospective clinical studies on esophageal cancer with local characteristics in Mianyang, which was reached the international leading level. In 2019, he presided over the research on the transformation of high-energy X-ray FLASH radiotherapy, which proved that high-energy X-ray has the FLASH effect for the first time in the world. The research results were published in Radiotherapy and Oncology magazine in 2021, and reported at the ASTRO conference. He has published more than 40 peer reviewed papers. His major areas of research are the comprehensive treatment of esophageal cancer and lung cancer, transformation research of FLASH radiotherapy and radionuclide targeted therapy.

PhD student in the Repair, Radiation and Innovative Cancer Therapies team. My project consists in identifying molecular biomarkers and cellular targets to predict the response of healthy lung tissue to different irradiation protocols including FLASH. I also worked on the development of new ex vivo models of organotypic lung slices to study the response of healthy tissue in the short term after irradiation.

Prof. Dr. Marco Durante is Director of the Biophysics Department at GSI Helmholtz Center for Heavy Ion Research (Darmstadt, Germany) and Full Professor of Physics at the Technical University of Darmstadt. He is also Adjunct Professor of Physics at the University of Naples Federico II in Italy, and at the Gunma College of Medicine in Japan. Dr. Durante got his Ph.D. in physics in 1992 at the University Federico II and has worked as postdoc at the Lawrence Berkeley Laboratory (Berkeley, CA, USA), NASA Lyndon B. Johnson Space Center (Houston, TX, USA), and NIRS-QST (Chiba, Japan). He is generally recognized as world leader in the field of particle radiobiology and medical physics and is co-author of over 45 papers in peer-reviewed scientific journals (h-index=59) and one patent on proton therapy (EU patent WO2013083333). He is currently chair of the the Particle Therapy Co-Operative Group (PTCOG). Dr. Durante was President of the International Association for Radiation Research (IARR) 2011-15, and is Associate Editor in several International scientific journals. He has received many grants to support his research, primarily by ESA, EU H2020, ERC, and BMBF and several awards for his research including the 2020 Failla award (RRS), 2013 Bacq & Alexander award (ERRS) and the 2013 IBA-Europhyscs award (EPS).

Marie Dutreix is a Biologist (Ph.D.), director of the laboratory at the Institut Curie, president of the “Société Française du Cancer” (2012-2017) and co-founder of the company “DNA Therapeutics” (bought by Onxeo in 2016). She is a specialist of genetic instability and biological effects of radiation. She developed new strategies to treat tumours resistant to radiotherapy/chemotherapy and discovered new DNA repair inhibitors (Dbait/AsiDNA). Her work extend from basic research on DNA repair mechanisms to clinical applications of the AsiDNA inhibitors and development of innovative protocols with the high-dose rate “FLASH” irradiation. She is co-director of the Institute of Nanotechnologies and Radiation based Therapies of the University Paris-Saclay, the GDR MI2B of CNRS, the Medico-scientific program of Institut Curie. She received numerous prizes the most recent being, the prize of the Academy of Science (2016). She was awarded “Chevalier de l’ordre National du Mérite” in 2013 and “Chevalier de l’ordre de la légion d’honneur” in 2017. 102 international publications, 12 patents.

Dr. Suparna Dutt is a senior scientist in the Department of Radiation Oncology/Radiation Therapy at Stanford University school of Medicine. She works with Dr. Billy W Loo, Jr MD PhD, and studies the in vivo effect of FLASH irradiation on the immune cells and DNA damage responses in preclinical models.